Apitope International NV has appointed Graham Roberts as development director for therapeutics with responsibility for research and development, in particular, the company’s ATX-MS-1467 project for multiple sclerosis which is partnered with Merck Serono.
Dr Roberts joins Apitope from the UK clinical research organisation, SRA Global Clinical Development Ltd, where he was global vice president of regulatory affairs and strategic drug development. Dr Roberts has also been project director and biologics manufacturing manager at British Biotech and before that, group manager of research at Celltech Group Plc. He obtained his PhD in biochemistry from the University of Cambridge. Apitope is headquartered in Belgium, but its therapeutic team is located in Bristol, UK.
Copyright 2009 Evernow Publishing Ltd